Adma Biologics, Inc. (NASDAQ: ADMA) has announced an ambitious capital return initiative target of approximately $200 million during 2026. This includes the execution of a $125 million accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association. The ASR agreement underscores the company’s strong financial position, durable free cash flow profile, and confidence in its long-term growth trajectory.
Under the terms of the ASR agreement, Adma will pay JPMorgan an aggregate upfront amount of $125 million and will initially receive approximately 6.4 million shares of its common stock on or about March 3, 2026, representing approximately 80% of the shares expected to be repurchased under the ASR.
Since the program’s authorization in May 2025, between prior repurchases and the ASR, Adma will have repurchased approximately $160 million of its common stock to date. Management believes these actions enhance long-term stockholder value and reflect a disciplined and opportunistic approach to capital allocation.
Adma Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company is also developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. Adma manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its Adma Biocenters subsidiary, Adma also operates as an FDA-approved source plasma collector in the U.S.
This capital return initiative and accelerated share repurchase highlight Adma Biologics’ confidence in its financial position and long-term growth prospects, and its commitment to driving value for its stockholders. Today the company's shares have moved -1.09% to a price of $17.31. Check out the company's full 8-K submission here.
